^
Association details:
| Biomarker: | MTAP deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | IDE397 (MAT2A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Excerpt:
...Evidence of homozygous loss of MTAP ([]) and/or MTAP deletion....
Trial ID:
Source:
Title:
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Excerpt:
...- Have evidence of homozygous loss of MTAP or MTAP deletion...
Trial ID:
Less C2 evidence
Source:
Title:
1278 - MAT2A inhibitor, IDE397, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts
Published date:
03/10/2021
Excerpt:
Administration of IDE397 resulted in TGI and/or tumor regression in MTAP-deleted CDX and PDX models. The HCT116 MTAP-deleted CDX model was more sensitive to IDE397 compared to the HCT116 MTAP-WT model. In a NSCLC CDX model, a dose dependent TGI was observed, with the higher doses leading to tumor regression. Anti-tumor activity is observed in MTAP-deleted PDX models, where IDE397 administration has resulted in TGI and tumor regressions. Xenograft studies indicate that IDE397 exhibits anti-tumor activity as a single agent in MTAP-deleted CDX models and in MTAP-deleted PDX models of NSCLC, pancreatic, bladder, head and neck, esophageal and gastric cancer.
